Browsing Tag
SNT-5505
2 posts
Syntara’s (ASX: SNT) AZALOX trial clears first safety hurdle and advances to final 200 mg cohort
Syntara Limited has advanced its AZALOX study into the final Phase 1b cohort after the first patients completed treatment without dose-limiting toxicities, keeping a preliminary Q4 2026 data release on track.
Syntara Limited raises A$8m as ASX:SNT advances amsulostat toward Phase 2b trial
Syntara has capital, catalysts, and dilution. The real question is whether amsulostat data can shift investor trust in ASX:SNT.